secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001824293-24-000078
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio regains compliance with Nasdaq continued listing standards
------------------------------------------------------------------

- Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).
- Scheduled hearing before Nasdaq Hearings Panel has been canceled.
- Now in compliance with all applicable continued listing standards on Nasdaq Capital Market.
- No financial impact or operational changes disclosed; CEO expresses focus on core business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000078/0001824293-24-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429324000078/val-20240702.htm
  HTML page:      https://secwatch.observer/filing/0001824293-24-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer